肝癌切除术后使用索拉非尼患者的预后因素分析

【摘要】 目的 探索肝细胞癌切除术后服用索拉非尼患者预后的影响因素。方法 回顾性分析2008年~2009年22例经病理证实的肝细胞肝癌手术切除且术后接受索拉非尼治疗的患者,选择10项临床、病理学因素,分析其对生存率的影响。结果 全组平均生存时间为11.72±1.46月,中位生存时间为16.50±3.50月,1年生存率为50.7%。影响预后的单因素为ECOG评分、临床分期、病理分级、AFP(P<0.05)。多因素分析表明,ECOG评分与生存率有显著相关性(P<0.05)。结论 ECOG评分较低、临床分期较早、病理分化较好、AFP较低者,索拉非尼疗效较好,患者预后亦较好;ECOG评分是肝癌术后服用索拉非尼患者生存的危险因素,可作为预测索拉非尼应用于肝癌术后患者疗效的指标之一。

Analysis on prognostic factors of postoperative hepatocellular carcinoma patients treated with sorafinib

Objective To investigate the prognostic factors of postoperative patients with hepatocellular carcinoma （HCC） treated with sorafinib. Methods From January 2008 to December 2009,22 patients underwent hepatectomy for HCC and treated with sorafenib, these patients were enrolled for reviewing their clinical characteristics, treatment and prognosis. Ten parameters contributing to survival rate （SR） were analyzed. Results The mean survival time of 22 patients was 11.72＋1.47 months, while the median survival time was 16.50_＋3.50 months. The one year survival rate was 50.7%. ECOG score, clinical stage, pathological classification and AFP were risk factors of prognosis by univariable analysis （P〈O.05）： A muhivariable analysis showed that ECOG score was independent prognostic factor （P〈O.05）. Conclusion Lower ECOG score and AFP, earlier clinical stage and higher pathological classificatio＇n Could indicate better clinical outcome when the patients treated with sorafinib after operation. ECOG score is the important risk factor for prognosis on postoperative HCC patients treated with sorafinib, which can be used as one of the predictive indicators of effect.